Jasper Therapeutics is a biotechnology company dedicated to developing therapies that target mast cells and stem cells to address chronic diseases. Their primary focus is on briquilimab, a monoclonal antibody designed to selectively deplete mast cells and diseased stem cells. This innovative approach aims to enhance the safety and efficacy of hematopoietic stem cell transplants and gene therapies, particularly for conditions such as chronic urticaria, asthma, and rare genetic disorders like sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. The company is leveraging a collaborative model that includes experienced biopharma professionals, academic institutions, and healthcare investors to advance their therapeutic pipeline.

Briquilimab's mechanism of action involves inhibiting the c-Kit signaling pathway, which is crucial for mast cell activation and survival. The ongoing clinical studies, including Phase 1b/2a trials, are evaluating the safety, pharmacokinetics, and therapeutic efficacy of briquilimab in various settings. Preliminary results indicate promising outcomes, such as durable remissions in patients undergoing allogeneic hematopoietic cell transplantation. By focusing on targeted therapies that minimize the need for traditional conditioning regimens, Jasper Therapeutics aims to provide safer and more effective treatment options for patients with mast and stem cell-related diseases.

United States

Jasper Therapeutics is a biotechnology company focused on targeting mast cells and stem cells to treat chronic diseases. Their mission is to make a significant difference in the lives of patients suffering from these conditions.

Allergy

Hematologic Diseases

Immune System Diseases

Jasper Therapeutics

Severe combined immunodeficiency due to complete RAG1/2 deficiency

<p class="font_8">Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria.</p>

Jasper Therapeutics

Company Details